Our results show that the interleukin 15 pathway appeared to increase in activity in SSTR2-high groups in 92.31% of cancers, and the interleukin 2 pathway appeared to increase in activity in SSTR2-high groups in 96.15% of cancers (Figures 2N,O). This evidence concerns the gene IL2 and cancer.